Sierra Oncology Inc (DNAI) opened at $1.99 on Monday. Sierra Oncology Inc has a fifty-two week low of $1.10 and a fifty-two week high of $2.25.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/11/06/sierra-oncology-inc-dnai-to-release-quarterly-earnings-on-wednesday.html.
About Sierra Oncology
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
What are top analysts saying about Sierra Oncology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sierra Oncology Inc and related companies.